Cala Health

Cala Health, Inc. was founded in 2014 and is headquartered in the San Francisco Bay Area. It is a bioelectronic medical company aiming to change the standard of care for chronic diseases. The company has pioneered a new type of electronic medicine called peripheral nerve therapy, which treats chronic diseases through external electronic stimulation of peripheral nerves. The company's wearable neuromodulation therapy combines innovations in neuroscience and technology to provide personalized peripheral nerve stimulation. Its vertically integrated business model is transforming the delivery of prescription therapies. Cala Trio is currently the only non-invasive prescription therapy for essential tremor (ET) and also shows potential in the fields of neurological disorders, cardiac diseases, and mental health conditions. The device received FDA approval in April 2018, becoming the leading non-invasive targeted nerve stimulation treatment for ET. With its vertically integrated business model, Cala Trio has entered the U.S. market, reshaping the delivery of prescription therapies: patients can obtain prescriptions through in-person consultations or telemedicine appointments, and Cala Trio can conveniently reach patients' homes, where Cala Health provides personalized instruction based on the patient’s learning style.